Ixoreal Biomed, the manufacturer of the advanced ashwagandha extract KSM-66®, has signed an exclusive agreement with Australia’s largest contract manufacturer Lipa Pharmaceuticals for the territories of Australia and New Zealand. KSM-66 can be used in many applications including nutraceuticals, functional foods and beverages.
“Ixoreal is delighted to partner with the industry leader Lipa Pharmaceuticals in Australia and New Zealand as our companies share the strong belief and deep commitment to the philosophy of discovering and bringing to market the best science-based ingredients that nature has to offer,” said Kartikeya Baldwa director of Ixoreal Biomed.